Articles

FDA Approves Neutroval for Severe Neutropenia
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
The FDA approved tbo-filgrastim (Neutro­val; Sicor Biotech UAB, a member of Teva Corporation) to reduce the duration of severe neutropenia in pa­tients with cancer receiving chemotherapy.
Read More
Regorafenib Latest Therapy Approved for Metastatic Colorectal Cancer
FDA Approvals, News & Updates
October 2012, Vol 3, No 7
Using its priority review process, the US Food and Drug Administration (FDA) approved the oral multikinase inhibitor regorafenib (Stivarga; Bayer HealthCare Pharmaceuticals) for the treatment of patients with metastatic colorectal cancer (mCRC).
Read More
Indirect Costs of Metastatic Breast Cancer Are Substantial
By Caroline Helwick
Breast Cancer Symposium
October 2012, Vol 3, No 7
San Francisco, CA—The indirect costs of metastatic breast cancer are substantial and are much higher than the costs of early breast cancer, according to what may be the first study to compare costs related to lost productivity in the population with breast cancer.
Read More
Many Emerging Biomarkers, but Few Are Clinically Applicable
By Caroline Helwick
October 2012, Vol 3, No 7
Houston, TX—Despite much talk about biomarkers and a field that is exploding, only a few biomarkers can be reliably and routinely used to improve patient care at this time, according to Peter G. Ellis, MD, Deputy Director of Clinical Services, Associate Chief Medical Officer, University of Pittsburgh Medical Center Cancer Centers.
Read More
Updated Data Confirm Survival Benefits with T-DM1 in Breast Cancer and with Regorafenib in Colon Cancer
By Phoebe Starr
ESMO 2012 Conference, ESMO
October 2012, Vol 3, No 7
Vienna, Austria—The updated analyses of 2 major studies of drugs that were recently approved by the US Food and Drug Administration (FDA) confirm the benefits of trastuzumab emtansine (T-DM1) in patients with advanced HER2-positive breast cancer and of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).
Read More
Crizotinib Superior to Chemotherapy, Extends Median Survival in First Head-to-Head Trial
By Audrey Andrews
ESMO 2012 Conference, ESMO
October 2012, Vol 3, No 7
Vienna, Austria—In the first head-to-head phase 3 clinical trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) proved more effective than standard chemotherapy with pemetrexed (Alimta) or docetaxel (Taxotere) as a second-line treatment for patients with non–small-cell lung cancer (NSCLC) and the ALK genetic abnormality.
Read More
Continuation of Bevacizumab Beyond Progression Improves Outcome in Patients with Metastatic Colorectal Cancer
By Caroline Helwick
ESMO 2012 Conference, ESMO
October 2012, Vol 3, No 7
Vienna, Austria—More support for the continuation of treatment with bevacizumab beyond disease progression in patients with metastatic colorectal cancer was reported at the 2012 European Society for Medical Oncology (ESMO) Congress, validating a small but growing body of pre­vious data.
Read More
Use of Intensity-Modulated Radiotherapy Increasing and Costly in the Management of Head and Neck Cancers, but Value Unknown
Head and Neck Cancer
September 2012, Vol 3, No 6
Toronto, Canada—The popularity of intensity-modulated radiotherapy (IMRT) for head and neck cancer has climbed rapidly in recent years. How­ever, the extra cost associated with this treatment modality may not equate with improved value, according to researchers from the University of California at Los Angeles (UCLA), who presented their analysis at the 2012 International Conference on Head and Neck Cancer.
Read More
Carfilzomib a New Option for the Treatment of Patients with Relapsed, Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent
By Lynne Lederman, PhD, Medical Writer
Drug Updates
September 2012, Vol 3, No 6

Multiple myeloma (MM), a clonal malignancy of plasma cells, is responsible for 10% to 15% of all hematologic malignancies and for 20% of deaths resulting from hematologic cancers.1,2 In most patients, MM evolves from monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic plasma-cell disorder.

Read More
Molecularly Targeted Agents Have Lower Rates of Severe Diarrhea than Standard Chemotherapy
Health Policy, Policies & Guidelines
September 2012, Vol 3, No 6

New York, NY—Diarrhea is a common side effect of standard chemo­therapy, but the risk is less well characterized with molecularly targeted agents, which may add to the risk of diarrhea when combined with standard chemo­therapy, according to Lowell Anthony, MD, Professor of Medicine, University of Kentucky, and Chief of Medical Oncology, UK HealthCare, Lexington, who discussed this topic at the 2012 Multinational Association of Supportive Care in Cancer Inter­national Symposium.

Read More

Page 280 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.